Muscle and movement study for weight loss medications
Part of Hormones & metabolism clinical trials.
This study looks at how anti-obesity medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) affect your muscles and movement. It may help researchers understand how to combine these drugs with exercise for better health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 59 years old for the main study (or over 60 for an observation group).
- You have a BMI over 27 with a weight-related health issue like high blood pressure or sleep apnea, or a BMI over 30 without those issues.
- You are about to start a new anti-obesity medication (semaglutide or tirzepatide) and plan to stay on it for at least 6 months.
- You do not have type 2 diabetes.
- You have not been exercising more than 60 minutes per week or doing strength training in the last 3 months.
- You have not lost more than 3% of your body weight in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at what happens to your body (especially muscle) when you take a newer weight-loss medication, either with or without adding an exercise program. It could help you understand how to best protect your muscle while losing weight.
This study tests an investigational medication, called NNC0721-8060, to see how it works in people with excess weight (overweight or obesity). It may help with weight loss, but is still in early human testing.
This study tests whether two weight-loss medications, semaglutide and tirzepatide, combined with an exercise program can help people with obesity lose weight. It may help you if you are looking for a structured medical approach to weight loss.
This study tests an oral medicine (semaglutide) to see if it helps adults with excess weight lose weight. It might offer an easier, pill-based treatment option for weight management.
This study tests whether a weight-loss medication (a GLP-1 agonist) can change how the brain works and help with long-term weight control. It involves brain scans and a closely monitored treatment plan.
This trial tests if two newer weight-loss medications, semaglutide and tirzepatide, can help slow the aging process in adults with obesity. It compares the drugs to each other and to a placebo to see which might offer anti-aging benefits beyond weight loss.
Hear when a new Obesity and Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.